Hong Kong
# |
Name |
Price to Book Ratio (P/B) |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
6.20 |
Jan. 14, 2025 | USD 14.74 | 7.67% |
|
Hong Kong |
|
2 |
3.18 |
Jan. 14, 2025 | USD 3.02 | 2.59% |
|
Hong Kong |
|
3 |
1.56 |
Jan. 14, 2025 | USD 0.37 | 1.03% |
|
Hong Kong |
|
4 |
1.18 |
Jan. 14, 2025 | USD 0.21 | 8.82% |
|
Hong Kong |
|
5 |
1.02 |
Jan. 14, 2025 | USD 0.39 | 0.30% |
|
Hong Kong |
|
6 |
0.82 |
Jan. 14, 2025 | USD 0.26 | 2.03% |
|
Hong Kong |
|
7 |
0.77 |
Jan. 14, 2025 | USD 0.83 | 3.07% |
|
Hong Kong |
The Biotechnology company in Hong Kong with the highest Price to Book Ratio (P/B) is BeiGene, Ltd. (HKSE: 6160.HK) at 6.20.
The Biotechnology company in Hong Kong with the lowest Price to Book Ratio (P/B) is Guangdong Hybribio Biotech Co.,Ltd. (Shenzhen Stock Exchange: 300639.SZ) at 0.77.
The top 10 Biotechnology companies in Hong Kong by Price to Book Ratio (P/B) are BeiGene, Ltd., HUTCHMED (China) Limited, Sino Biopharmaceutical Limited, Frontage Holdings Corporation, Sirnaomics Ltd., KuangChi Science Limited and Guangdong Hybribio Biotech Co.,Ltd..
The bottom 10 Biotechnology companies in Hong Kong by Price to Book Ratio (P/B) are Guangdong Hybribio Biotech Co.,Ltd., KuangChi Science Limited, Sirnaomics Ltd., Frontage Holdings Corporation, Sino Biopharmaceutical Limited, HUTCHMED (China) Limited and BeiGene, Ltd..